Advancedbiotechnology

CRISPR-Cas9 in Detail

Overview

CRISPR-Cas9 edits genomes with RNA-guided precision: Cas9 nuclease, directed by a ~20-nt guide RNA, cuts DNA adjacent to a PAM (NGG), and cellular repair (NHEJ indels or HDR with a template) creates knockouts or precise edits. Adapted from bacterial immunity (Doudna/Charpentier 2012, Nobel 2020), it is cheap, fast, and multiplexable. Approved therapies (Casgevy for sickle cell) and base/prime editors extend it further.

Learning objectives

  • Explain guide RNA targeting and PAM
  • Describe NHEJ vs HDR editing outcomes
  • List applications from research to therapy
  • Discuss off-target and ethical issues

The mechanism

crRNA + tracrRNA (fused as sgRNA) guides Cas9 to a 20-bp target next to a PAM (NGG for SpCas9); Cas9's HNH and RuvC domains cut both strands 3 bp upstream of PAM. Bacteria evolved this as adaptive immunity: spacers from past phages guide destruction of new ones.

PAM required

No NGG, no cut: the PAM licenses Cas9 binding and prevents self-targeting of the CRISPR array.

Repair decides the edit

NHEJ: error-prone ligation makes indels -> frameshift knockouts (easiest). HDR: with a donor template, precise insertions/corrections, but inefficient in non-dividing cells. Base editors (deaminase fusions) change single letters without cutting; prime editors write longer edits via reverse transcriptase.

Knockout vs knock-in

NHEJ knockouts are routine; precise HDR knock-ins remain the efficiency bottleneck.

Applications

Genome-wide knockout screens, animal models in weeks, engineered crops, gene drives (malaria mosquitoes), diagnostics (SHERLOCK), and therapies: Casgevy (ex vivo BCL11A editing for sickle cell/beta-thalassemia, approved 2023), CAR-T enhancements, in vivo editing trials.

Ex vivo first

Approved therapies edit cells outside the body; in vivo delivery (liver, eye, muscle) is the frontier.

Ethics and off-targets

Off-target cuts (tolerated mismatches) are assayed by GUIDE-seq/CIRCLE-seq; high-fidelity Cas9 variants reduce them. He Jiankui's 2018 germline-edited babies drew global condemnation and prison: heritable editing is widely deemed premature. Somatic vs germline is the ethical bright line.

Somatic vs germline

Treating a patient (somatic) vs altering humanity's gene pool (germline): the central ethical divide.

Key points

  • sgRNA guides Cas9 to PAM-adjacent targets; dual nuclease domains cut both strands
  • NHEJ -> knockouts; HDR -> precise edits; base/prime editors expand options
  • Applications: screens, models, crops, diagnostics, approved sickle-cell therapy
  • Off-targets managed technically; germline editing ethically prohibited

Common misconceptions

✗ Myth: CRISPR always cuts DNA.

✓ Truth: Base editors and CRISPRi/a (dCas9 fusions) regulate or rewrite without double-strand breaks.

✗ Myth: Guide RNAs are perfectly specific.

✓ Truth: Mismatches are tolerated, especially distal to PAM: off-target assessment is mandatory.

Practice questions

Q1. Cas9 requires for cutting
  1. Any DNA
  2. A 20-bp match plus adjacent PAM (NGG)
  3. RNA only
  4. No guide
Answer: B.

Guide pairing plus PAM recognition licenses the double-strand break.

Q2. NHEJ repair of a Cas9 cut typically produces
  1. Precise correction
  2. Indels causing gene knockout
  3. No change
  4. Duplication
Answer: B.

Error-prone end joining creates frameshifting indels.

Q3. The first approved CRISPR therapy (Casgevy) treats
  1. Cancer
  2. Sickle cell disease / beta-thalassemia
  3. Diabetes
  4. Alzheimer's
Answer: B.

Ex vivo editing reactivating fetal hemoglobin, approved 2023.

Click a question to reveal the answer and explanation.

Frequently asked questions

What is a gene drive?

CRISPR cassettes that copy themselves onto homologous chromosomes, forcing inheritance >50%: proposed for malaria vector control, with ecological containment debates.

How does Casgevy treat sickle cell?

Patient stem cells are edited ex vivo to reactivate fetal hemoglobin, then reinfused: the disease mutation stays, but HbF compensates.

What won the 2020 Chemistry Nobel?

Doudna and Charpentier, for CRISPR-Cas9 genome editing (Mojica, Horvath and others' foundational work recognized separately).